Cardiogenic Shock Market
Cardiogenic Shock Market Analysis by Treatment Type (Cardiogenic Shock Treatment Drugs, Antiplatelet medication, Mechanical Circulatory Support (MCS) devices, Invasive Ventilation (endotracheal tube), In Vitro Test Kits), by End User, by Region - Global Market Insights 2022-2032
Analysis of Cardiogenic Shock market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Cardiogenic Shock Market Outlook (2022-2032)
The global cardiogenic shock market was valued at US$ 3.29 Billion in 2021 and is expected to reach US$ 6.32 Billion by 2032, expanding at a CAGR of 6.2% over the 2022-2032 time frame.
The drugs segment, under treatment type, dominated the global cardiogenic shock market in 2021 in terms of revenue and market share, accounting for 52.7% of the total market, and is expected to surge ahead at a CAGR of 7.8% over the forecast period (2022-2032).
Report Attributes |
Details |
|---|---|
|
Cardiogenic Shock Market Size (2021) |
US$ 3.29 Billion |
|
Estimated Market Value (2022) |
US$ 3.45 Billion |
|
Forecasted Market Value (2032) |
US$ 6.32 Billion |
|
Global Market Growth Rate (2022-2032) |
6.2% CAGR |
|
East Asia Market Share (2021) |
12.2% |
|
East Asia Market Growth Rate (2022-2032) |
7.7% CAGR |
|
China Market Growth Rate (2022-2032) |
8.4% CAGR |
|
Share of Top 5 Countries |
55% |
|
Key Market Players |
|
Cardiogenic shock treatment accounts for nearly 6.4% share of the global cardiovascular device market, which was estimated to be around US$ 51.9 Billion in 2021.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Cardiogenic Shock Treatment Demand Analysis (2017-2021) Compared to Market Outlook (2022-2032)
The global cardiogenic shock treatment devices and drugs market expanded at a CAGR of 4.1% over the last five years.
Cardiogenic shock is a situation where the heart fails to pump blood and oxygen to the cease organs and can be a reason for cease-organ failure. Cardiogenic shock results from a coronary heart attack and is life-threatening.
Signs of cardiogenic shock include chest pain, dizziness, fainting, shortness of breath, profuse sweating, nausea, and vomiting. Other reasons for cardiogenic shock include myocarditis or infection of the coronary heart muscles, endocarditis or contamination of the coronary heart valves, drug overdose, and a sedentary lifestyle.
According to the JACC: Heart Failure research paper, November 2020, cardiogenic shock is said to adversely affect acute myocardial infarction, as with the increasing population, patients have been clinically in a complex state. In 2022, CDC stated that, nearly 805,000 people in the U.S. suffer from heart attacks yearly.
Rising burden of cardiovascular diseases and growing incidence of cardiogenic shock (epidemiology), increasing ageing population, and growing economic burden are likely to stimulate the growth of the cardiogenic shock market.
Considering this, Fact.MR expects the worldwide cardiogenic shock market to expand at a CAGR of 6.2% over the forecast period (2022-2032).
What’s Mainly Driving Demand for Cardiogenic Shock Treatment Drugs & Devices?
“High Prevalence of Cardiovascular Disease and Advancements in Related Devices”
Cardiogenic shock management necessitates a collaborative effort involving organizational methodologies, accurate diagnosis using equipment such as electrocardiogram, echocardiogram, coronary angiography etc., and therapeutic management to preserve blood flow.
Collaborative techniques entail interpersonal contact among team members and healthcare experts to develop a strategy protocol for the start and management of high-risk situations, as well as patient safety precautions. These cardiogenic shock treatments aid in improving patient outcomes and lengthening survival times.
Furthermore, the shock team, which entails interventional cardiology, critical care medicine, anesthesiology, cardiothoracic surgery, perfusion services, nursing, and rehabilitation, is quite beneficial. Use of interdisciplinary action has had a favourable influence on patient care.
Despite the high rate of cardiovascular disease mortality and substantially lower R&D spending, cardiovascular care has shown improvements in patient management.
What’s Restraining Growth of Cardiogenic Shock Market Players?
“High Cost Associated with Treatment and Mechanical-assisted Devices”
For illnesses such as coronary heart disease, cardiomyopathy, and congenital heart disease, a heart transplant is done, in which, a diseased heart is replaced with a healthy donor’s heart.
With the rise in cardiovascular disorders, including systolic dysfunction, valvular dysfunction, diastolic dysfunction, cardiac arrhythmias, coronary artery disease and other mechanical complications, the need for heart transplants has increased.
According to the American Transplant Foundation, the number of deceased donors in the United States increased 6% from 11,870 in 2019 to 12,588 in 2020.
A heart transplant is the gold standard treatment; however, the number of donors for heart transplants appears to be decreasing with the number of recipients increasing.
The expense of treating related diseases remains high due to the high death rate of cardiovascular diseases. If cardiogenic shock is not recognized correctly, it can progress to significant multi-organ failure.
Despite the ease with which physicians can deliver mechanical circulatory devices for treatment, the expense of the standard of care might be a stumbling block to the expansion of the cardiogenic shock treatment market.
Country-wise Insights
What is the U.S. Market Stance for Cardiogenic Shock Treatment?
The U.S. accounted for over 88% of the North America cardiogenic shock market in 2021, owing to the development of many treatment facilities and rising investments in the healthcare sector.
Moreover, approvals by the U.S. FDA are increasing and resulting in more products getting launched, making the U.S a high revenue-generating country.
- For instance, in February 2021, Abbott’s CardioMEMS™ HF system received FDA approval to support patients battling earlier-stage heart failure.
Also, rise in awareness about cardiac disorders offers lucrative opportunities for the U.S. market for cardiogenic shock treatment.
Will Germany Be a Lucrative Market for Cardiogenic Shock?
Germany accounted for 22.9% market share in the Europe cardiogenic shock market in 2021.
As the geriatric population is increasing, Germany is focusing on various research & development programs and supporting different startups, which is boosting the cardiogenic shock market in the country.
- For instance, in November 2020, Bayer initiated support for five new startup companies as part of the company’s G4A Digital Health Partnerships Program.
The focus is to foster the development of a digital health ecosystem while driving forward integrated healthcare solutions in the fields of cardiometabolic and renal diseases, oncology, and women’s health.
What are the Factors Fueling Demand for Cardiogenic Shock Solutions in China?
China accounted for 43.4% of the East Asia cardiogenic shock market in 2021.
The provision of major manufacturing services to meet clinical needs and high production of raw materials for drug manufacturing are some of the key trends driving market expansion in China. This is ultimately strengthening its position in the East Asia market.
Cost-effective production of devices generates a high revenue share for China in the region’s cardiogenic shock treatment market.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Category-wise Insights
Why is Demand for Cardiogenic Shock Drugs Gaining Traction?
By treatment type, drugs held the highest market share of 52.7% in 2021, with the segment expected to expand at 7.8% CAGR over the forecast period. This is being influenced by increasing research & development on cardiogenic shock treatment.
Furthermore, as drugs are considered the first line of treatment and are cost-effective, they are preferable in comparison to other treatment options, which makes this segment the most lucrative for the forecast period.
Impact of COVID-19 Crisis
The outbreak of COVID-19 had a brief impact on the cardiogenic shock market due to lockdowns and temporary shutdowns. Supply and demand were jolted by the massive infection spread, which staggered the supply of cardiogenic shock equipment.
The COVID-19 pandemic resulted in a short-term downside on the growth of the cardiogenic shock market, as most healthcare resources were diverted to tackle the COVID-19 pandemic situation. There was also a subsequent decline in the manufacturing of products for cardiovascular treatment due to COVID-19.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Competitive Landscape
Key manufacturers of cardiogenic shock treatment products are actively focusing on the expansion of their portfolios by introducing new products that are technologically advanced, as a strategy to maintain their position in the global cardiogenic shock market
- In August 2021, the U.S. FDA approved the expansion of the peripheral artery disease (PAD) indication for Xarelto™ plus aspirin.
Similarly, recent developments related to companies operating in the cardiogenic shock market have been tracked by the team at Fact.MR, which are available in the full report.
Key Segments Covered in Cardiogenic Shock Industry Research
-
By Treatment Type :
- Treatment Drugs
- Inotropic Agents
- Thrombolytic
- Vasopressors
- Norepinephrine
- Epinephrine
- Vasopressin
- Phenylephrine
- Dobutamine
- Antiplatelet medication
- Other blood-thinning medications
- Cardiogenic Shock Treatment Devices
- Mechanical Circulatory Support (MCS) devices
- Intravascular Micro axial LVAD
- Intra-Aortic Balloon Pump (IABP)
- Axial Flow Pumps
- Extracorporeal Membrane Oxygenation (ECMO)
- Artery Bypass Pumps
- Invasive Ventilation (endotracheal tube)
- In Vitro Test Kits
- N-Terminal Pro-B-Type Natriuretic Peptide (NT-ProBNP)
- Troponin
- Treatment Drugs
-
By End User :
- Hospitals
- Ambulatory Surgical centers
- Cardiac Catheterization Labs
- Office-Based Clinics
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa (MEA)
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusion and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Application Innovation / Development Trends 4. Key Success Factors 4.1. Key Promotional Strategies 4.2. Value Chain Analysis 4.3. PESTLE Analysis 4.4. PORTER Analysis 5. Key Inclusions 5.1. Patient Journey 5.2. Disease Epidemiology, By Region 5.3. Reimbursement Landscape 6. Market Background 6.1. Macro-Economic Factors 6.1.1. Global GDP Growth Outlook 6.1.2. Global Healthcare Outlook 6.1.3. Global Healthcare Expenditure Outlook 6.2. Forecast Factors - Relevance & Impact 6.2.1. Increasing Spending on Healthcare Per Capita 6.2.2. Increasing Spending for Healthcare Infrastructure Development Post COVID-19 Pandemic 6.2.3. Minimization in Surgical Practices 6.2.4. Increasing Lifestyle Disorders Impacting Cardiac Health 6.2.5. Prevalence of Cardiac Shock as a Result of AMI (acute Myocardial Infarction) 6.2.6. Increasing Geriatric Population. 6.3. Market Dynamics 6.3.1. Drivers 6.3.2. Restraints 6.3.3. Opportunity Analysis 7. COVID19 Crisis Analysis 7.1. Current COVID19 Statistics and Probable Future Impact 7.2. Current GDP Projection and Probable Impact 7.3. Current Economic Projection as compared to 2008 Economic analysis 7.4. COVID19 and Impact Analysis, by Country 7.5. 2020 Market Scenario 8. Global Cardiogenic Shock Market Demand Value (US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032 8.1. Historical Market Value (US$ Mn) Analysis, 2017-2021 8.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032 8.2.1. Y-o-Y Growth Trend Analysis 8.2.2. Absolute $ Opportunity Analysis 9. Global Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022–2032, Treatment Type 9.1. Introduction / Key Findings 9.2. Historical Market Value (US$ Mn) Treatment Type, 2017-2021 9.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Treatment Type, 2022–2032 9.3.1. Drugs 9.3.1.1. Inotropic Agents 9.3.1.2. Thrombolytic 9.3.1.3. Vasopressors 9.3.1.3.1. Norepinephrine 9.3.1.3.2. Epinephrine 9.3.1.3.3. Vasopressin 9.3.1.3.4. Phenylephrine 9.3.1.3.5. Dobutamine 9.3.1.4. Antiplatelet medication 9.3.1.5. Other blood-thinning medications 9.3.2. Devices 9.3.2.1. Mechanical Circulatory Support (MCS) devices 9.3.2.1.1. Intravascular Micro axial LVAD 9.3.2.1.2. Intra?Aortic Balloon Pump (IABP) 9.3.2.1.3. Axial Flow Pumps 9.3.2.1.4. Extracorporeal Membrane Oxygenation (ECMO) 9.3.2.1.5. Artery Bypass Pumps 9.3.2.2. Invasive Ventilation (endotracheal tube) 9.3.3. In vitro test kits 9.3.3.1. N?Terminal Pro?B?Type Natriuretic Peptide (NT?ProBNP) 9.3.3.2. Troponin I 9.4. Market Attractiveness Analysis Treatment Type 10. Global Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022–2032, By End User 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By End User, 2017-2021 10.3. Current and Future Market Material (US$ Mn) Analysis and Forecast By End User, 2022–2032 10.3.1. Hospitals 10.3.2. Ambulatory Surgical centers 10.3.3. Cardiac Catheterization Labs 10.3.4. Office Based Clinics 10.4. Market Attractiveness Analysis By End User 11. Global Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022–2032, by Region 11.1. Introduction 11.2. Historical Market Value (US$ Mn) Analysis By Region, 2017-2021 11.3. Current Market Value (US$ Mn) Analysis and Forecast By Region, 2022–2032 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022–2032 12.1. Introduction 12.2. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 12.3. Market Value (US$ Mn) Forecast By Market Taxonomy, 2022–2032 12.3.1. By Country 12.3.1.1. U.S. 12.3.1.2. Canada 12.3.2. Treatment Type 12.3.3. By End User 12.4. Market Attractiveness Analysis 12.5. Market Trends 12.6. Key Market Participants - Intensity Mapping 13. Latin America Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022–2032 13.1. Introduction 13.2. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 13.3. Market Value (US$ Mn) Forecast By Market Taxonomy, 2022–2032 13.3.1. By Country 13.3.1.1. Brazil 13.3.1.2. Mexico 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. Treatment Type 13.3.3. By End User 13.4. Market Attractiveness Analysis 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 14. Europe Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022–2032 14.1. Introduction 14.2. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 14.3. Market Value (US$ Mn) Forecast By Market Taxonomy2022–2032 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. U.K. 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Russia 14.3.1.8. Rest of Europe 14.3.2. Treatment Type 14.3.3. By End User 14.4. Market Attractiveness Analysis 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 15. South Asia Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022–2032 15.1. Introduction 15.2. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 15.3. Market Value (US$ Mn) Forecast By Market Taxonomy2022–2032 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Thailand 15.3.1.3. Indonesia 15.3.1.4. Malaysia 15.3.1.5. Rest of South Asia 15.3.2. Treatment Type 15.3.3. By End User 15.4. Market Attractiveness Analysis 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 16. East Asia Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022–2032 16.1. Introduction 16.2. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 16.3. Market Value (US$ Mn) Forecast By Market Taxonomy, 2022–2032 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. Treatment Type 16.3.3. By End User 16.4. Market Attractiveness Analysis 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 17. Oceania Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022–2032 17.1. Introduction 17.2. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 17.3. Market Value (US$ Mn) Forecast By Market Taxonomy, 2022–2032 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. Treatment Type 17.3.3. By End User 17.4. Market Attractiveness Analysis 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 18. Middle East and Africa Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022–2032 18.1. Introduction 18.2. Historical Market Value (US$ Mn) Trend Analysis By Value Taxonomy, 2017-2021 18.3. Market Value (US$ Mn) Forecast By Market Taxonomy, 2022–2032 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Turkey 18.3.1.3. South Africa 18.3.1.4. Rest of Middle East and Africa 18.3.2. Treatment Type 18.3.3. By End User 18.4. Market Attractiveness Analysis 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 19. Key & Emerging Countries Cardiogenic Shock Market Analysis and Forecast 2022 & 2032 19.1. U.S. Cardiogenic Shock Market Analysis 19.1.1. Treatment Type 19.1.2. By End User 19.2. Canada Cardiogenic Shock Market Analysis 19.2.1. Treatment Type 19.2.2. By End User 19.3. Brazil Cardiogenic Shock Market Analysis 19.3.1. Treatment Type 19.3.2. By End User 19.4. Mexico Cardiogenic Shock Market Analysis 19.4.1. Treatment Type 19.4.2. By End User 19.5. Argentina Cardiogenic Shock Market Analysis 19.5.1. Treatment Type 19.5.2. By End User 19.6. U.K. Cardiogenic Shock Market Analysis 19.6.1. Treatment Type 19.6.2. By End User 19.7. Germany Cardiogenic Shock Market Analysis 19.7.1. Treatment Type 19.7.2. By End User 19.8. France Cardiogenic Shock Market Analysis 19.8.1. Treatment Type 19.8.2. By End User 19.9. Italy Cardiogenic Shock Market Analysis 19.9.1. Treatment Type 19.9.2. By End User 19.10. Spain Cardiogenic Shock Market Analysis 19.10.1. Treatment Type 19.10.2. By End User 19.11. BENELUX Cardiogenic Shock Market Analysis 19.11.1. Treatment Type 19.11.2. By End User 19.12. Russia Cardiogenic Shock Market Analysis 19.12.1. Treatment Type 19.12.2. By End User 19.13. China Cardiogenic Shock Market Analysis 19.13.1. Treatment Type 19.13.2. By End User 19.14. Japan Cardiogenic Shock Market Analysis 19.14.1. Treatment Type 19.14.2. By End User 19.15. South Korea Cardiogenic Shock Market Analysis 19.15.1. Treatment Type 19.15.2. By End User 19.16. India Cardiogenic Shock Market Analysis 19.16.1. Treatment Type 19.16.2. By End User 19.17. Malaysia Cardiogenic Shock Market Analysis 19.17.1. Treatment Type 19.17.2. By End User 19.18. Thailand Cardiogenic Shock Market Analysis 19.18.1. Treatment Type 19.18.2. By End User 19.19. Indonesia Cardiogenic Shock Market Analysis 19.19.1. Treatment Type 19.19.2. By End User 19.20. Rest of South Asia Cardiogenic Shock Market Analysis 19.20.1. Treatment Type 19.20.2. By End User 19.21. Australia Cardiogenic Shock Market Analysis 19.21.1. Treatment Type 19.21.2. By End User 19.22. New Zealand Cardiogenic Shock Market Analysis 19.22.1. Treatment Type 19.22.2. By End User 19.23. GCC Countries Cardiogenic Shock Market Analysis 19.23.1. Treatment Type 19.23.2. By End User 19.24. South Africa Cardiogenic Shock Market Analysis 19.24.1. Treatment Type 19.24.2. By End User 19.25. Turkey Cardiogenic Shock Market Analysis 19.25.1. Treatment Type 19.25.2. By End User 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Concentration 20.3. Market Share Analysis of Top Players 20.4. Market Presence Analysis 20.4.1. Regional footprint of Players 20.4.2. Channel Foot Print by Players 21. Competition Deep Dive 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive 21.3.1. ABBOTT Diagnostics 21.3.1.1. Overview 21.3.1.2. Service Portfolio 21.3.1.3. Key Financials 21.3.1.4. Strategy Overview 21.3.2. Angiodynamics, Inc. 21.3.2.1. Overview 21.3.2.2. Service Portfolio 21.3.2.3. Key Financials 21.3.2.4. Strategy Overview 21.3.3. Boston Scientific Corporation 21.3.3.1. Overview 21.3.3.2. Service Portfolio 21.3.3.3. Key Financials 21.3.3.4. Strategy Overview 21.3.4. Edwards Life Science Corporation 21.3.4.1. Overview 21.3.4.2. Service Portfolio 21.3.4.3. Key Financials 21.3.4.4. Strategy Overview 21.3.5. Cook Medical 21.3.5.1. Overview 21.3.5.2. Service Portfolio 21.3.5.3. Key Financials 21.3.5.4. Strategy Overview 21.3.6. Medtronic Inc. 21.3.6.1. Overview 21.3.6.2. Service Portfolio 21.3.6.3. Key Financials 21.3.6.4. Strategy Overview 21.3.7. Terumo Medical Corporation 21.3.7.1. Overview 21.3.7.2. Service Portfolio 21.3.7.3. Key Financials 21.3.7.4. Strategy Overview 21.3.8. bioMerieux Inc. 21.3.8.1. Overview 21.3.8.2. Service Portfolio 21.3.8.3. Key Financials 21.3.8.4. Strategy Overview 21.3.9. Roche Diagnostics 21.3.9.1. Overview 21.3.9.2. Service Portfolio 21.3.9.3. Key Financials 21.3.9.4. Strategy Overview 21.3.10. Beckman Coulter (Danaher Corporation) 21.3.10.1. Overview 21.3.10.2. Service Portfolio 21.3.10.3. Key Financials 21.3.10.4. Strategy Overview 21.3.11. SIEMENS AG 21.3.11.1. Overview 21.3.11.2. Service Portfolio 21.3.11.3. Key Financials 21.3.11.4. Strategy Overview 21.3.12. GE Healthcare 21.3.12.1. Overview 21.3.12.2. Service Portfolio 21.3.12.3. Key Financials 21.3.12.4. Strategy Overview 21.3.13. Nihon Kohden 21.3.13.1. Overview 21.3.13.2. Service Portfolio 21.3.13.3. Key Financials 21.3.13.4. Strategy Overview 21.3.14. Philips Healthcare 21.3.14.1. Overview 21.3.14.2. Service Portfolio 21.3.14.3. Key Financials 21.3.14.4. Strategy Overview 21.3.15. Mindray Bio-Medical Electronics Co., Ltd. 21.3.15.1. Overview 21.3.15.2. Service Portfolio 21.3.15.3. Key Financials 21.3.15.4. Strategy Overview 21.3.16. Drägerwerk AG & Co. KGaA 21.3.16.1. Overview 21.3.16.2. Service Portfolio 21.3.16.3. Key Financials 21.3.16.4. Strategy Overview 21.3.17. Mylan Pharmaceuticals 21.3.17.1. Overview 21.3.17.2. Service Portfolio 21.3.17.3. Key Financials 21.3.17.4. Strategy Overview 21.3.18. Alembic Pharmaceuticals Ltd 21.3.18.1. Overview 21.3.18.2. Service Portfolio 21.3.18.3. Key Financials 21.3.18.4. Strategy Overview 21.3.19. Alkem Laboratories Ltd 21.3.19.1. Overview 21.3.19.2. Service Portfolio 21.3.19.3. Key Financials 21.3.19.4. Strategy Overview 21.3.20. Cadila Pharmaceuticals Ltd 21.3.20.1. Overview 21.3.20.2. Service Portfolio 21.3.20.3. Key Financials 21.3.20.4. Strategy Overview 21.3.21. Sanofi S.A. 21.3.21.1. Overview 21.3.21.2. Service Portfolio 21.3.21.3. Key Financials 21.3.21.4. Strategy Overview 21.3.22. Sun Pharmaceutical Industries Ltd 21.3.22.1. Overview 21.3.22.2. Service Portfolio 21.3.22.3. Key Financials 21.3.22.4. Strategy Overview 21.3.23. Teva Pharmaceutical Industries 21.3.23.1. Overview 21.3.23.2. Service Portfolio 21.3.23.3. Key Financials 21.3.23.4. Strategy Overview 22. Assumptions and Acronyms Used 23. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 02: Global Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 03: Global Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 04: Global Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By End User
Table 05: Global Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Region
Table 06: North America Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 07: North America Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 08: North America Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 9: North America Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By End User
Table 10: North America Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Country
Table 11: Latin America Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 12: Latin America Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 13: Latin America Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 14: Latin America Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By End User
Table 15: Latin America Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Country
Table 16: Europe Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 17: Europe Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 18: Europe Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 19: Europe Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By End User
Table 20: Europe Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Country
Table 21: South Asia Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 22: South Asia Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 23: South Asia Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 24: South Asia Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By End User
Table 25: South Asia Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Country
Table 26: East Asia Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 27: East Asia Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 28: East Asia Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 29: East Asia Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By End User
Table 30: East Asia Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Country
Table 31: Oceania Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 32: Oceania Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 33: Oceania Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 34: Oceania Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By End User
Table 35: Oceania Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Country
Table 36: MEA Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 37: MEA Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 38: MEA Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Treatment Type
Table 39: MEA Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By End User
Table 40: MEA Cardiogenic Shock Market Analysis 2017–2021 and Forecast 2022-2032, By Country
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Cardiogenic Shock Market Value (US$ Mn) Analysis, 2017–2021
Figure 02: Global Cardiogenic Shock Market Value (US$ Mn) Forecast, 2022 - 2032
Figure 03: Global Cardiogenic Shock Market Absolute $ Opportunity, 2022 - 2032
Figure 04: Global Cardiogenic Shock Market Value Share (%) Analysis 2022 & 2032, By Treatment Type
Figure 05: Global Cardiogenic Shock Market Y-o-Y Growth (%) Analysis 2022-2032, By Treatment Type
Figure 06: Global Cardiogenic Shock Market Attractiveness Analysis, By Treatment Type
Figure 07: Global Cardiogenic Shock Market Value Share (%) Analysis 2022 & 2032, By End User
Figure 08: Global Cardiogenic Shock Market Y-o-Y Growth (%) Analysis 2022-2032, By End User
Figure 09: Global Cardiogenic Shock Market Attractiveness Analysis, By End User
Figure 10: Global Cardiogenic Shock Market Value Share (%) Analysis 2022 & 2032, By Region
Figure 11: Global Cardiogenic Shock Market Y-o-Y Growth (%) Analysis 2022-2032, By Region
Figure 12: Global Cardiogenic Shock Market Attractiveness Analysis, By Region
Figure 13: North America Cardiogenic Shock Market Value Share By Treatment Type 2022 (E)
Figure 14: North America Cardiogenic Shock Market Value Share By End User 2022 (E)
Figure 15: North America Cardiogenic Shock Market Value Share By Country 2022 (E)
Figure 16: North America Cardiogenic Shock Market Value Analysis (US$ Mn), 2017-2021
Figure 17: North America Cardiogenic Shock Market Value Forecast (US$ Mn), 2022 - 2032
Figure 18: North America Cardiogenic Shock Market Attractiveness Analysis By Treatment Type , 2022- 2032
Figure 19: North America Cardiogenic Shock Market Attractiveness Analysis by End User, 2022 - 2032
Figure 20: North America Cardiogenic Shock Market Attractiveness Analysis, By Country 2022 - 2032
Figure 21: Latin America Cardiogenic Shock Market Value Share By Treatment Type 2022 (E)
Figure 22: Latin America Cardiogenic Shock Market Value Share By End User 2022 (E)
Figure 23: Latin America Cardiogenic Shock Market Value Share By Country 2022 (E)
Figure 24: Latin America Cardiogenic Shock Market Value Analysis (US$ Mn), 2017-2021
Figure 25: Latin America Cardiogenic Shock Market Value Forecast (US$ Mn), 2022 - 2032
Figure 26: Latin America Cardiogenic Shock Market Attractiveness Analysis By Treatment Type , 2022 - 2032
Figure 27: Latin America Cardiogenic Shock Market Attractiveness Analysis by End User, 2022 - 2032
Figure 28: Latin America Cardiogenic Shock Market Attractiveness Analysis, By Country 2022 - 2032
Figure 29: Europe Cardiogenic Shock Market Value Share By Treatment Type 2022 (E)
Figure 30: Europe Cardiogenic Shock Market Value Share By End User 2022 (E)
Figure 31: Europe Cardiogenic Shock Market Value Share By Country 2022 (E)
Figure 32: Europe Cardiogenic Shock Market Value Analysis (US$ Mn), 2017-2021
Figure 33: Europe Cardiogenic Shock Market Value Forecast (US$ Mn), 2022 - 2032
Figure 34: Europe Cardiogenic Shock Market Attractiveness Analysis By Treatment Type , 2022 - 2032
Figure 35: Europe Cardiogenic Shock Market Attractiveness Analysis by End User, 2022 - 2032
Figure 36: Europe Cardiogenic Shock Market Attractiveness Analysis, By Country 2022 - 2032
Figure 37: South Asia Cardiogenic Shock Market Value Share By Treatment Type 2022 (E)
Figure 38: South Asia Cardiogenic Shock Market Value Share By End User 2022 (E)
Figure 39: South Asia Cardiogenic Shock Market Value Share By Country 2022 (E)
Figure 40: South Asia Cardiogenic Shock Market Value Analysis (US$ Mn), 2017-2021
Figure 41: South Asia Cardiogenic Shock Market Value Forecast (US$ Mn), 2022 - 2032
Figure 42: South Asia Cardiogenic Shock Market Attractiveness Analysis By Treatment Type , 2022- 2032
Figure 43: South Asia Cardiogenic Shock Market Attractiveness Analysis by End User, 2022 - 2032
Figure 44: South Asia Cardiogenic Shock Market Attractiveness Analysis, By Country 2022 - 2032
Figure 45: East Asia Cardiogenic Shock Market Value Share By Treatment Type 2022 (E)
Figure 46: East Asia Cardiogenic Shock Market Value Share By End User 2022 (E)
Figure 47: East Asia Cardiogenic Shock Market Value Share By Country 2022 (E)
Figure 48: East Asia Cardiogenic Shock Market Value Analysis (US$ Mn), 2017-2021
Figure 49: East Asia Cardiogenic Shock Market Value Forecast (US$ Mn), 2022 - 2032
Figure 50: East Asia Cardiogenic Shock Market Attractiveness Analysis By Treatment Type , 2022- 2032
Figure 51: East Asia Cardiogenic Shock Market Attractiveness Analysis by End User, 2022 - 2032
Figure 52: East Asia Cardiogenic Shock Market Attractiveness Analysis, By Country 2022 - 2032
Figure 53: Oceania Cardiogenic Shock Market Value Share By Treatment Type 2022 (E)
Figure 54: Oceania Cardiogenic Shock Market Value Share By End User 2022 (E)
Figure 55: Oceania Cardiogenic Shock Market Value Share By Country 2022 (E)
Figure 56: Oceania Cardiogenic Shock Market Value Analysis (US$ Mn), 2017-2021
Figure 57: Oceania Cardiogenic Shock Market Value Forecast (US$ Mn), 2022 - 2032
Figure 58: Oceania Cardiogenic Shock Market Attractiveness Analysis By Treatment Type , 2022- 2032
Figure 59: Oceania Cardiogenic Shock Market Attractiveness Analysis by End User, 2022 - 2032
Figure 60: Oceania Cardiogenic Shock Market Attractiveness Analysis, By Country 2022 - 2032
Figure 61: MEA Cardiogenic Shock Market Value Share By Treatment Type 2022 (E)
Figure 62: MEA Cardiogenic Shock Market Value Share By End User 2022 (E)
Figure 63: MEA Cardiogenic Shock Market Value Share By Country 2022 (E)
Figure 64: MEA Cardiogenic Shock Market Value Analysis (US$ Mn), 2017-2021
Figure 65: MEA Cardiogenic Shock Market Value Forecast (US$ Mn), 2022 - 2032
Figure 66: MEA Cardiogenic Shock Market Attractiveness Analysis By Treatment Type , 2022- 2032
Figure 67: MEA Cardiogenic Shock Market Attractiveness Analysis by End User, 2022 - 2032
Figure 68: MEA Cardiogenic Shock Market Attractiveness Analysis, By Country 2022 - 2032
Figure 69: U.S Market Value Proportion Analysis, 2021
Figure 70: Global Vs. U.S Growth Comparison
Figure 71: U.S. Cardiogenic Shock Market Share Analysis (%) By Treatment Type , 2022 & 2032
Figure 72: U.S. Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 73: Canada Market Value Proportion Analysis, 2021
Figure 74: Global Vs. Canada Growth Comparison
Figure 75: Canada Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 76: Canada Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 77: Brazil Market Value Proportion Analysis, 2021
Figure 78: Global Vs. Brazil Growth Comparison
Figure 79: Brazil Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 80: Brazil Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 81: Mexico Market Value Proportion Analysis, 2021
Figure 82: Global Vs. Mexico Growth Comparison
Figure 83: Mexico Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 84: Mexico Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 85: Argentina Market Value Proportion Analysis, 2021
Figure 86: Global Vs. Argentina Growth Comparison
Figure 87: Argentina Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 88: Argentina Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 89: U.K. Market Value Proportion Analysis, 2021
Figure 90: Global Vs. U.K. Growth Comparison
Figure 91: U.K Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 92: U.K Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 93: Germany Market Value Proportion Analysis, 2021
Figure 94: Global Vs. Germany Growth Comparison
Figure 95: Germany Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 96: Germany Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 97: France Market Value Proportion Analysis, 2021
Figure 98: Global Vs. France Growth Comparison
Figure 99: France Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 100: France Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 101: Italy Market Value Proportion Analysis, 2021
Figure 102: Global Vs. Italy Growth Comparison
Figure 103: Italy Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 104: Italy Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 105: Spain Market Value Proportion Analysis, 2021
Figure 106: Global Vs. Spain Growth Comparison
Figure 107: Spain Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 108: Spain Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 109: Russia Market Value Proportion Analysis, 2021
Figure 110: Global Vs. Russia Growth Comparison
Figure 111: Russia Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 112: Russia Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 113: BENELUX Market Value Proportion Analysis, 2021
Figure 114: Global Vs. Poland Growth Comparison
Figure 115: BENELUX Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 116: BENELUX Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 117: India Market Value Proportion Analysis, 2021
Figure 118: Global Vs. India Growth Comparison
Figure 119: India Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 120: India Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 121: Thailand Market Value Proportion Analysis, 2021
Figure 122: Global Vs. Thailand Growth Comparison
Figure 123: Thailand Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 124: Thailand Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 125: Indonesia Market Value Proportion Analysis, 2021
Figure 126: Global Vs. Indonesia Growth Comparison
Figure 127: Indonesia Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 128: Indonesia Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 129: Malaysia Market Value Proportion Analysis, 2022
Figure 130: Global Vs. Malaysia Growth Comparison
Figure 131: Malaysia Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 132: Malaysia Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 133: China Market Value Proportion Analysis, 2021
Figure 134: Global Vs. China Growth Comparison
Figure 135: China Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 136: China Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 137: South Korea Market Value Proportion Analysis, 2021
Figure 138: Global Vs. South Korea Growth Comparison
Figure 139: South Korea Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 140: South Korea Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 141: Japan Market Value Proportion Analysis, 2021
Figure 142: Global Vs. Japan Growth Comparison
Figure 143: Japan Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 144: Japan Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 145: Australia Market Value Proportion Analysis, 2021
Figure 146: Global Vs. Australia Growth Comparison
Figure 147: Australia Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 148: Australia Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 149: New Zealand Market Value Proportion Analysis, 2021
Figure 150: Global Vs. New Zealand Growth Comparison
Figure 151: France Cardiogenic Shock Market Share Analysis (%) By Treatment Type , 2022 & 2032
Figure 152: New Zealand Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 153: GCC Countries Market Value Proportion Analysis, 2021
Figure 154: Global Vs. GCC Countries Growth Comparison
Figure 155: GCC Countries Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 156: GCC Countries Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Figure 157: South Africa Market Value Proportion Analysis, 2021
Figure 158: Global Vs. South Africa Growth Comparison
Figure 159: South Africa Cardiogenic Shock Market Share Analysis (%) By Treatment Type , 2022 & 2032
Figure 160: South Africa Cardiogenic Shock Market Share Analysis (%) by End User Type, 2022 & 2032
Figure 161: Turkey Market Value Proportion Analysis, 2021
Figure 162: Global Vs. South Africa Growth Comparison
Figure 163: Turkey Cardiogenic Shock Market Share Analysis (%) by Treatment , 2022 & 2032
Figure 164: Turkey Cardiogenic Shock Market Share Analysis (%) by End User, 2022 & 2032
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the demand outlook for cardiogenic shock treatment?
The global market for cardiogenic shock is expected to reach US$ 6.32 Billion by the end of 2032.
What are the top 5 countries driving demand for cardiogenic shock treatment?
The U.S., Germany, U.K., China, and France are driving most growth of the cardiogenic shock market.
What is the market outlook for the U.S.?
The U.S. accounted for 88.2% share of the North American market share in 2021.
At what percentage is demand for cardiogenic shock treatment expected to register growth in Europe?
The Europe market is predicted to expand at 5.2% CAGR over the forecast period.
Who are the leading companies manufacturing cardiogenic shock devices and drugs?
Top companies in this market are ABIOMED, Bayer AG, Abbott, Viatris, Par Pharmaceutical, Getinge Group, Terumo Corporation, Medtronic, AstraZeneca, and F. Hoffman-La Roche Ltd.
How is the market faring in South Korea and Japan?
The South Korea cardiogenic shock market is expected to exhibit 5.2% CAGR, with the Japanese market growing even faster at 7.8% CAGR.
How much is the cardiogenic shock market valued at?
The global cardiogenic shock market was worth US$ 3.29 Bn in 2021.
At what CAGR did the market expand over the past 5 years?
Revenue from the cardiogenic shock market increased at a CAGR of 4.1% from 2017 to 2021.
Cardiogenic Shock Market